[Carteolol: general practice-oriented assessment of the effectiveness and tolerance of a new beta-blocker in the treatment of glaucoma].
During an open multicenter field study the new beta-blocking agent Carteolol, in 1% and 2% solution, proved to be effective and safe in the treatment of 178 patients suffering from glaucoma. On average, IOP was lowered by 5.8 to 18.7 mm Hg in nontreated and by 4.8 to 17.8 mm Hg in pretreated patients. In more than 90% of the cases both the patients and the investigators judged the treatment to be good, or better than the previous therapy. Side affects occurred in less than 3% of the cases.
Schnaudigel
O E
OE
Augenklinik der Johann Wolfgang Goethe-Universität Frankfurt/Main.
Becker
H
H
Fuchs
H B
HB
D002354:Carteolol / Q000009:adverse effects / Q000627:therapeutic use*; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D009798:Ocular Hypertension / Q000188:drug therapy*; D011412:Propanolamines / Q000627:therapeutic use*
D011412:Propanolamines; D002354:Carteolol
Carteolol: Praxisgerechte Prüfung von Wirksamkeit und Verträglichkeit eines neuen Betablockers in der Behandlung des Glaukoms.